APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vitamin K Antagonists (VKA)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vitamin K Antagonists (VKA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025194 pages

Choose your research edition.

Industry ResearchVitamin K Antagonists (VKA) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Vitamin K Antagonists (VKA) Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Vitamin K Antagonists (VKA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vitamin K Antagonists (VKA) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vitamin K Antagonists (VKA) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vitamin K Antagonists (VKA) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vitamin K Antagonists (VKA) include Sanofi, Johnson & Johnson, Lilly, Pfizer, Bayer, AstraZeneca, The Medicines Company, Otsuka and Genentech (Roche), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vitamin K Antagonists (VKA) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vitamin K Antagonists (VKA) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vitamin K Antagonists (VKA) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vitamin K Antagonists (VKA) market size, projected growth trends, production technologies, key applications, and end-use industries.

Vitamin K Antagonists (VKA) Segment by Company

Sanofi

Johnson & Johnson

Lilly

Pfizer

Bayer

AstraZeneca

The Medicines Company

Otsuka

Genentech (Roche)

Daiichi Sankyo

Bristol-Myers Squibb

Boehringer Ingelheim

Aspen

Vitamin K Antagonists (VKA) Segment by Type

Oral Vitamin K Antagonists

Injection Vitamin K Antagonists

Vitamin K Antagonists (VKA) Segment by Application

AF

ACS/MI

VTE

Others

Vitamin K Antagonists (VKA) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vitamin K Antagonists (VKA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vitamin K Antagonists (VKA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vitamin K Antagonists (VKA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vitamin K Antagonists (VKA) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vitamin K Antagonists (VKA) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vitamin K Antagonists (VKA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vitamin K Antagonists (VKA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vitamin K Antagonists (VKA) Industry Trends Table 2. Vitamin K Antagonists (VKA) Industry Drivers Table 3. Vitamin K Antagonists (VKA) Industry Opportunities and Challenges Table 4. Vitamin K Antagonists (VKA) Industry Restraints Table 5. Global Vitamin K Antagonists (VKA) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vitamin K Antagonists (VKA) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vitamin K Antagonists (VKA) Sales by Manufacturers (W Tons) & (2021-2026) Table 8. Global Vitamin K Antagonists (VKA) Sales Market Share by Manufacturers Table 9. Global Vitamin K Antagonists (VKA) Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Vitamin K Antagonists (VKA) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vitamin K Antagonists (VKA) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vitamin K Antagonists (VKA) Manufacturers, Product Type & Application Table 13. Global Vitamin K Antagonists (VKA) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vitamin K Antagonists (VKA) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Vitamin K Antagonists Table 17. Major Manufacturers of Injection Vitamin K Antagonists Table 18. Global Vitamin K Antagonists (VKA) Sales by Type 2021 VS 2025 VS 2032 (W Tons) Table 19. Global Vitamin K Antagonists (VKA) Sales by Type (2021-2026) & (W Tons) Table 20. Global Vitamin K Antagonists (VKA) Sales by Type (2027-2032) & (W Tons) Table 21. Global Vitamin K Antagonists (VKA) Sales Market Share by Type (2021-2026) Table 22. Global Vitamin K Antagonists (VKA) Sales Market Share by Type (2027-2032) Table 23. Global Vitamin K Antagonists (VKA) Revenue by Type 2021 VS 2025 VS 2032 (W Tons) Table 24. Global Vitamin K Antagonists (VKA) Revenue by Type (2021-2026) & (W Tons) Table 25. Global Vitamin K Antagonists (VKA) Revenue by Type (2027-2032) & (W Tons) Table 26. Global Vitamin K Antagonists (VKA) Revenue Market Share by Type (2021-2026) Table 27. Global Vitamin K Antagonists (VKA) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of AF Table 29. Major Manufacturers of ACS/MI Table 30. Major Manufacturers of VTE Table 31. Major Manufacturers of Others Table 32. Global Vitamin K Antagonists (VKA) Sales by Application 2021 VS 2025 VS 2032 (W Tons) Table 33. Global Vitamin K Antagonists (VKA) Sales by Application (2021-2026) & (W Tons) Table 34. Global Vitamin K Antagonists (VKA) Sales by Application (2027-2032) & (W Tons) Table 35. Global Vitamin K Antagonists (VKA) Sales Market Share by Application (2021-2026) Table 36. Global Vitamin K Antagonists (VKA) Sales Market Share by Application (2027-2032) Table 37. Global Vitamin K Antagonists (VKA) Revenue by Application 2021 VS 2025 VS 2032 (W Tons) Table 38. Global Vitamin K Antagonists (VKA) Revenue by Application (2021-2026) & (W Tons) Table 39. Global Vitamin K Antagonists (VKA) Revenue by Application (2027-2032) & (W Tons) Table 40. Global Vitamin K Antagonists (VKA) Revenue Market Share by Application (2021-2026) Table 41. Global Vitamin K Antagonists (VKA) Revenue Market Share by Application (2027-2032) Table 42. Global Vitamin K Antagonists (VKA) Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Table 43. Global Vitamin K Antagonists (VKA) Sales by Region (2021-2026) & (W Tons) Table 44. Global Vitamin K Antagonists (VKA) Sales Market Share by Region (2021-2026) Table 45. Global Vitamin K Antagonists (VKA) Sales Forecasted by Region (2027-2032) & (W Tons) Table 46. Global Vitamin K Antagonists (VKA) Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 48. North America Vitamin K Antagonists (VKA) Sales by Country (2021-2026) & (W Tons) Table 49. North America Vitamin K Antagonists (VKA) Sales by Country (2027-2032) & (W Tons) Table 50. Europe Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 51. Europe Vitamin K Antagonists (VKA) Sales by Country (2021-2026) & (W Tons) Table 52. Europe Vitamin K Antagonists (VKA) Sales by Country (2027-2032) & (W Tons) Table 53. Asia Pacific Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 54. Asia Pacific Vitamin K Antagonists (VKA) Sales by Country (2021-2026) & (W Tons) Table 55. Asia Pacific Vitamin K Antagonists (VKA) Sales by Country (2027-2032) & (W Tons) Table 56. South America, Middle East and Africa Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Tons) Table 57. South America, Middle East and Africa Vitamin K Antagonists (VKA) Sales by Country (2021-2026) & (W Tons) Table 58. South America, Middle East and Africa Vitamin K Antagonists (VKA) Sales by Country (2027-2032) & (W Tons) Table 59. Global Vitamin K Antagonists (VKA) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Vitamin K Antagonists (VKA) Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Vitamin K Antagonists (VKA) Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Vitamin K Antagonists (VKA) Revenue Market Share by Region (2021-2026) Table 63. Global Vitamin K Antagonists (VKA) Revenue Market Share by Region (2027-2032) Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sanofi Vitamin K Antagonists (VKA) Product Portfolio Table 68. Sanofi Recent Development Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Johnson & Johnson Vitamin K Antagonists (VKA) Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. Lilly Company Information Table 75. Lilly Business Overview Table 76. Lilly Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Lilly Vitamin K Antagonists (VKA) Product Portfolio Table 78. Lilly Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Vitamin K Antagonists (VKA) Product Portfolio Table 83. Pfizer Recent Development Table 84. Bayer Company Information Table 85. Bayer Business Overview Table 86. Bayer Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Bayer Vitamin K Antagonists (VKA) Product Portfolio Table 88. Bayer Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. AstraZeneca Vitamin K Antagonists (VKA) Product Portfolio Table 93. AstraZeneca Recent Development Table 94. The Medicines Company Company Information Table 95. The Medicines Company Business Overview Table 96. The Medicines Company Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. The Medicines Company Vitamin K Antagonists (VKA) Product Portfolio Table 98. The Medicines Company Recent Development Table 99. Otsuka Company Information Table 100. Otsuka Business Overview Table 101. Otsuka Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Otsuka Vitamin K Antagonists (VKA) Product Portfolio Table 103. Otsuka Recent Development Table 104. Genentech (Roche) Company Information Table 105. Genentech (Roche) Business Overview Table 106. Genentech (Roche) Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Genentech (Roche) Vitamin K Antagonists (VKA) Product Portfolio Table 108. Genentech (Roche) Recent Development Table 109. Daiichi Sankyo Company Information Table 110. Daiichi Sankyo Business Overview Table 111. Daiichi Sankyo Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Daiichi Sankyo Vitamin K Antagonists (VKA) Product Portfolio Table 113. Daiichi Sankyo Recent Development Table 114. Bristol-Myers Squibb Company Information Table 115. Bristol-Myers Squibb Business Overview Table 116. Bristol-Myers Squibb Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Bristol-Myers Squibb Vitamin K Antagonists (VKA) Product Portfolio Table 118. Bristol-Myers Squibb Recent Development Table 119. Boehringer Ingelheim Company Information Table 120. Boehringer Ingelheim Business Overview Table 121. Boehringer Ingelheim Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Boehringer Ingelheim Vitamin K Antagonists (VKA) Product Portfolio Table 123. Boehringer Ingelheim Recent Development Table 124. Aspen Company Information Table 125. Aspen Business Overview Table 126. Aspen Vitamin K Antagonists (VKA) Sales (W Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Aspen Vitamin K Antagonists (VKA) Product Portfolio Table 128. Aspen Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Vitamin K Antagonists (VKA) Distributors List Table 132. Vitamin K Antagonists (VKA) Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Vitamin K Antagonists (VKA) Product Image Figure 2. Global Vitamin K Antagonists (VKA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vitamin K Antagonists (VKA) Market Size (2021-2032) & (US$ Million) Figure 4. Global Vitamin K Antagonists (VKA) Sales (2021-2032) & (W Tons) Figure 5. Global Vitamin K Antagonists (VKA) Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Vitamin K Antagonists (VKA) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Vitamin K Antagonists Image Figure 9. Injection Vitamin K Antagonists Image Figure 10. Global Vitamin K Antagonists (VKA) Sales by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 11. Global Vitamin K Antagonists (VKA) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Vitamin K Antagonists (VKA) Sales Market Share by Type (2021-2032) Figure 13. Global Vitamin K Antagonists (VKA) Revenue by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 14. Global Vitamin K Antagonists (VKA) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Vitamin K Antagonists (VKA) Revenue Market Share by Type (2021-2032) Figure 16. AF Image Figure 17. ACS/MI Image Figure 18. VTE Image Figure 19. Others Image Figure 20. Global Vitamin K Antagonists (VKA) Sales by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 21. Global Vitamin K Antagonists (VKA) Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Vitamin K Antagonists (VKA) Sales Market Share by Application (2021-2032) Figure 23. Global Vitamin K Antagonists (VKA) Revenue by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 24. Global Vitamin K Antagonists (VKA) Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Vitamin K Antagonists (VKA) Revenue Market Share by Application (2021-2032) Figure 26. North America Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 27. North America Vitamin K Antagonists (VKA) Sales Market Share by Country (2021-2032) Figure 28. U.S. Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 29. Canada Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 30. Mexico Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 31. Europe Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 32. Europe Vitamin K Antagonists (VKA) Sales Market Share by Country (2021-2032) Figure 33. Germany Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 34. France Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 35. U.K. Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 36. Italy Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 37. Netherlands Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 38. Asia Pacific Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 39. Asia Pacific Vitamin K Antagonists (VKA) Sales Market Share by Country (2021-2032) Figure 40. China Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 41. Japan Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 42. South Korea Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 43. Southeast Asia Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 44. India Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 45. Australia Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 46. South America, Middle East and Africa Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 47. South America, Middle East and Africa Vitamin K Antagonists (VKA) Sales Market Share by Country (2021-2032) Figure 48. Brazil Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 49. South Africa Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 50. Saudi Arabia Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 51. Turkey Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 52. Argentina Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 53. UAE Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 54. Egypt Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 55. Chile Vitamin K Antagonists (VKA) Sales and Growth Rate (2021-2032) & (W Tons) Figure 56. Global Vitamin K Antagonists (VKA) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Vitamin K Antagonists (VKA) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Vitamin K Antagonists (VKA) Revenue (2021-2032) & (US$ Million) Figure 59. North America Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Vitamin K Antagonists (VKA) Revenue (2021-2032) & (US$ Million) Figure 61. Europe Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Vitamin K Antagonists (VKA) Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Vitamin K Antagonists (VKA) Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Vitamin K Antagonists (VKA) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Vitamin K Antagonists (VKA) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Vitamin K Antagonists
  • Injection Vitamin K Antagonists
Applications
  • AF
  • ACS/MI
  • VTE
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Lilly
  • Pfizer
  • Bayer
  • AstraZeneca
  • The Medicines Company
  • Otsuka
  • Genentech (Roche)
  • Daiichi Sankyo
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Aspen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vitamin K Antagonists (VKA) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vitamin K Antagonists (VKA) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vitamin K Antagonists (VKA) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vitamin K Antagonists (VKA) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vitamin K Antagonists (VKA) Market Dynamics
  1. 2.1 Vitamin K Antagonists (VKA) Industry Trends
  2. 2.2 Vitamin K Antagonists (VKA) Industry Drivers
  3. 2.3 Vitamin K Antagonists (VKA) Industry Opportunities and Challenges
  4. 2.4 Vitamin K Antagonists (VKA) Industry Restraints
3 Vitamin K Antagonists (VKA) Market by Manufacturers
  1. 3.1 Global Vitamin K Antagonists (VKA) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vitamin K Antagonists (VKA) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vitamin K Antagonists (VKA) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vitamin K Antagonists (VKA) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vitamin K Antagonists (VKA) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vitamin K Antagonists (VKA) Manufacturers, Product Type & Application
  7. 3.7 Global Vitamin K Antagonists (VKA) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vitamin K Antagonists (VKA) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vitamin K Antagonists (VKA) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vitamin K Antagonists (VKA) Tier 1, Tier 2, and Tier 3
4 Vitamin K Antagonists (VKA) Market by Type
  1. 4.1 Vitamin K Antagonists (VKA) Type Introduction
  2. 4.1.1 Oral Vitamin K Antagonists
  3. 4.1.2 Injection Vitamin K Antagonists
  4. 4.2 Global Vitamin K Antagonists (VKA) Sales by Type
  5. 4.2.1 Global Vitamin K Antagonists (VKA) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vitamin K Antagonists (VKA) Sales by Type (2021-2032)
  7. 4.2.3 Global Vitamin K Antagonists (VKA) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Vitamin K Antagonists (VKA) Revenue by Type
  9. 4.3.1 Global Vitamin K Antagonists (VKA) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vitamin K Antagonists (VKA) Revenue by Type (2021-2032)
  11. 4.3.3 Global Vitamin K Antagonists (VKA) Revenue Market Share by Type (2021-2032)
5 Vitamin K Antagonists (VKA) Market by Application
  1. 5.1 Vitamin K Antagonists (VKA) Application Introduction
  2. 5.1.1 AF
  3. 5.1.2 ACS/MI
  4. 5.1.3 VTE
  5. 5.1.4 Others
  6. 5.2 Global Vitamin K Antagonists (VKA) Sales by Application
  7. 5.2.1 Global Vitamin K Antagonists (VKA) Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Vitamin K Antagonists (VKA) Sales by Application (2021-2032)
  9. 5.2.3 Global Vitamin K Antagonists (VKA) Sales Market Share by Application (2021-2032)
  10. 5.3 Global Vitamin K Antagonists (VKA) Revenue by Application
  11. 5.3.1 Global Vitamin K Antagonists (VKA) Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Vitamin K Antagonists (VKA) Revenue by Application (2021-2032)
  13. 5.3.3 Global Vitamin K Antagonists (VKA) Revenue Market Share by Application (2021-2032)
6 Global Vitamin K Antagonists (VKA) Sales by Region
  1. 6.1 Global Vitamin K Antagonists (VKA) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vitamin K Antagonists (VKA) Sales by Region (2021-2032)
  3. 6.2.1 Global Vitamin K Antagonists (VKA) Sales by Region (2021-2026)
  4. 6.2.2 Global Vitamin K Antagonists (VKA) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vitamin K Antagonists (VKA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vitamin K Antagonists (VKA) Revenue by Region
  1. 7.1 Global Vitamin K Antagonists (VKA) Revenue by Region
  2. 7.1.1 Global Vitamin K Antagonists (VKA) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vitamin K Antagonists (VKA) Revenue by Region (2021-2026)
  4. 7.1.3 Global Vitamin K Antagonists (VKA) Revenue by Region (2027-2032)
  5. 7.1.4 Global Vitamin K Antagonists (VKA) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vitamin K Antagonists (VKA) Revenue (2021-2032)
  8. 7.2.2 North America Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vitamin K Antagonists (VKA) Revenue (2021-2032)
  11. 7.3.2 Europe Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vitamin K Antagonists (VKA) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vitamin K Antagonists (VKA) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vitamin K Antagonists (VKA) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Vitamin K Antagonists (VKA) Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Vitamin K Antagonists (VKA) Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Lilly
  14. 8.3.1 Lilly Company Information
  15. 8.3.2 Lilly Business Overview
  16. 8.3.3 Lilly Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lilly Vitamin K Antagonists (VKA) Product Portfolio
  18. 8.3.5 Lilly Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Vitamin K Antagonists (VKA) Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Vitamin K Antagonists (VKA) Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Vitamin K Antagonists (VKA) Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 The Medicines Company
  38. 8.7.1 The Medicines Company Company Information
  39. 8.7.2 The Medicines Company Business Overview
  40. 8.7.3 The Medicines Company Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 The Medicines Company Vitamin K Antagonists (VKA) Product Portfolio
  42. 8.7.5 The Medicines Company Recent Developments
  43. 8.8 Otsuka
  44. 8.8.1 Otsuka Company Information
  45. 8.8.2 Otsuka Business Overview
  46. 8.8.3 Otsuka Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Otsuka Vitamin K Antagonists (VKA) Product Portfolio
  48. 8.8.5 Otsuka Recent Developments
  49. 8.9 Genentech (Roche)
  50. 8.9.1 Genentech (Roche) Company Information
  51. 8.9.2 Genentech (Roche) Business Overview
  52. 8.9.3 Genentech (Roche) Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Genentech (Roche) Vitamin K Antagonists (VKA) Product Portfolio
  54. 8.9.5 Genentech (Roche) Recent Developments
  55. 8.10 Daiichi Sankyo
  56. 8.10.1 Daiichi Sankyo Company Information
  57. 8.10.2 Daiichi Sankyo Business Overview
  58. 8.10.3 Daiichi Sankyo Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Daiichi Sankyo Vitamin K Antagonists (VKA) Product Portfolio
  60. 8.10.5 Daiichi Sankyo Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Vitamin K Antagonists (VKA) Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Vitamin K Antagonists (VKA) Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Aspen
  74. 8.13.1 Aspen Company Information
  75. 8.13.2 Aspen Business Overview
  76. 8.13.3 Aspen Vitamin K Antagonists (VKA) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Aspen Vitamin K Antagonists (VKA) Product Portfolio
  78. 8.13.5 Aspen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vitamin K Antagonists (VKA) Value Chain Analysis
  2. 9.1.1 Vitamin K Antagonists (VKA) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vitamin K Antagonists (VKA) Production Mode & Process
  6. 9.2 Vitamin K Antagonists (VKA) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vitamin K Antagonists (VKA) Distributors
  9. 9.2.3 Vitamin K Antagonists (VKA) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst